The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1
about
Why do HIV-1 and HIV-2 use different pathways to develop AZT resistance?Structures of HIV-1 reverse transcriptase with pre- and post-translocation AZTMP-terminated DNA.Crystal engineering of HIV-1 reverse transcriptase for structure-based drug designN348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutationsThe Role of Nucleotide Excision by Reverse Transcriptase in HIV Drug Resistance.Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition.The "Connection" Between HIV Drug Resistance and RNase HNucleoside analog resistance caused by insertions in the fingers of human immunodeficiency virus type 1 reverse transcriptase involves ATP-mediated excision.The HBV drug entecavir - effects on HIV-1 replication and resistanceThe K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutationsHighly active antiretroviral therapies are effective against HIV-1 cell-to-cell transmission.Molecular impact of the M184V mutation in human immunodeficiency virus type 1 reverse transcriptase.Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistanceEffect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibilitySelection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.Retrovirus reverse transcriptases containing a modified YXDD motif.Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistanceHIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.Hypersusceptibility mechanism of Tenofovir-resistant HIV to EFdA.Aptamers that recognize drug-resistant HIV-1 reverse transcriptaseThymidine analogue resistance suppression by V75I of HIV-1 reverse transcriptase: effects of substituting valine 75 on stavudine excision and discrimination.Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1.Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations.The Y181C substitution in 3'-azido-3'-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse transcriptase suppresses the ATP-mediated repair of the 3'-azido-3'-deoxythymidine 5'-monophosphate-terminated primer.Trapping HIV-1 reverse transcriptase before and after translocation on DNA.HIV drug resistance testing among patients failing second line antiretroviral therapy. Comparison of in-house and commercial sequencing.HIV cell-to-cell transmission: effects on pathogenesis and antiretroviral therapyStructural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase.Identification of a novel resistance (E40F) and compensatory (K43E) substitution in HIV-1 reverse transcriptase.Physiological Mg2+ Conditions Significantly Alter the Inhibition of HIV-1 and HIV-2 Reverse Transcriptases by Nucleoside and Non-Nucleoside Inhibitors in Vitro.Biochemical studies on the mechanism of human immunodeficiency virus type 1 reverse transcriptase resistance to 1-(beta-D-dioxolane)thymine triphosphate.A role of template cleavage in reduced excision of chain-terminating nucleotides by human immunodeficiency virus type 1 reverse transcriptase containing the M184V mutation.AZT resistance of simian foamy virus reverse transcriptase is based on the excision of AZTMP in the presence of ATP.The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.AZT resistance alters enzymatic properties and creates an ATP-binding site in SFVmac reverse transcriptase.An integrated molecular dynamics, principal component analysis and residue interaction network approach reveals the impact of M184V mutation on HIV reverse transcriptase resistance to lamivudine.Mechanistic studies to understand the progressive development of resistance in human immunodeficiency virus type 1 reverse transcriptase to abacavir.
P2860
Q25256872-4283C5F1-4F0A-42CA-B3D2-11FA7EB4FABCQ27640046-CC9BC1E4-0AD3-4FBB-9F08-A36D8B927185Q27651402-37EFB104-ABF7-4D69-B1A5-E99C08FF0C36Q33869951-BE41D368-BDF1-4E10-85FC-AE9806637294Q33889635-00FD26DA-45F4-4E61-92D3-2180F5A5711CQ33896402-7D945FE9-92E6-491C-A017-9CDAF415876EQ34313605-FA07493C-3642-4111-8742-3E157831D432Q34345605-79686297-D87D-4F45-B38B-36BCCEDF3E30Q34639926-7B780E53-5134-4CA6-8646-8595AF6CE30EQ34647936-4C55FC1B-D961-49F7-8A48-1708901149C8Q35105679-DB68530A-60CB-4AA1-90F7-7BD134AE6F74Q35566910-C6853F83-A4BE-4D4C-A0EE-0CB7AC282111Q35576015-9B0E0D36-8EB2-496C-B1DD-4600C4B6FCC9Q35941273-00B83651-F5AA-4805-BEA7-13871393FABAQ35947607-6A6E7CF3-3940-4140-9852-9FBE120E4D4BQ36186797-92E31A63-3986-4EE6-B6DE-9CE5527012A5Q36290768-EAFCB252-9BD4-4309-B0E6-1570B25F6FBDQ36501787-2D546742-2F04-4274-BD0B-801AC47601E4Q36558909-B26FF1FC-F525-4893-9EA2-9F11274E6A02Q36964321-C8FE24DC-6020-44DB-AF47-DA957EE13820Q36986716-0034C19B-C106-476C-B033-71B06D0D31C3Q37432131-119A8DF2-8884-40B2-BDED-BC027B24E435Q37492877-72B44F1F-D539-4702-AB8D-0238481F264DQ37859395-04AC04CF-A8D4-4E26-8DDF-8983E67054E9Q38339368-0B5F8588-7D97-4EAC-94D5-C8100658A762Q38344427-EBE3754C-E99C-439B-B162-464CF761385CQ38351813-149CC535-E37B-46E3-87F0-45F7FCEF48E2Q38358259-F132C69E-5D49-483F-A62A-2A31930F6E75Q38375479-1AEEFFFF-A222-44C0-9BB0-E85EF0B23ECAQ38376002-7AC0014D-EABD-4884-A83D-7745B6B11414Q39912641-ABBA094D-5082-48F9-82CD-97997B49AC49Q40013658-98DF3C19-212A-4465-9F94-3DCBAC170984Q40432241-8BB8F0B5-18BE-4080-BC24-F335DF706E7CQ41856023-E9500A29-9ACF-4E8C-8E00-B21C0AB7157BQ41862836-B567EDF3-2ABB-4158-B178-D32438F96A70Q41878118-B56B9948-03AA-43ED-A11B-1737C86CE027Q42117884-1B007F60-FC27-4B35-BCE6-08ACE7BB85CEQ42152706-99931357-7A02-4BEF-8C42-83680B27D6A7Q42212355-9CC7A18D-E46F-463D-80A1-F7A9942CEA3FQ44102100-F23DF1DC-5FFF-4E79-ACEA-17F46B9D8520
P2860
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The M184V mutation reduces the ...... immunodeficiency virus type 1
@ast
The M184V mutation reduces the ...... immunodeficiency virus type 1
@en
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate
@nl
type
label
The M184V mutation reduces the ...... immunodeficiency virus type 1
@ast
The M184V mutation reduces the ...... immunodeficiency virus type 1
@en
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate
@nl
prefLabel
The M184V mutation reduces the ...... immunodeficiency virus type 1
@ast
The M184V mutation reduces the ...... immunodeficiency virus type 1
@en
The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate
@nl
P2093
P2860
P1433
P1476
The M184V mutation reduces the ...... immunodeficiency virus type 1
@en
P2093
Edward Arnold
Paul L Boyer
Stefan G Sarafianos
P2860
P304
P356
10.1128/JVI.76.7.3248-3256.2002
P407
P577
2002-04-01T00:00:00Z